Invesco Ltd. 4 D Molecular Therapeutics, Inc. Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 27,425 shares of FDMT stock, worth $213,640. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,425

Previous 27,452 0.1%

Holding current value

$213,640

Previous $576,000 48.61%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$10.81 - $27.22 $291 - $734	-27 Reduced 0.1%	27,425 $296,000
Q2 2024 Aug 13, 2024	SELL	$20.93 - $30.01 $4,541 - $6,512	-217 Reduced 0.78%	27,452 $576,000
Q1 2024 May 14, 2024	BUY	$17.03 - $35.87 $231,454 - $487,509	13,591 Added 96.54%	27,669 $881,000
Q4 2023 Feb 12, 2024	SELL	$9.76 - $21.25 $33,164 - $72,207	-3,398 Reduced 19.44%	14,078 $285,000
Q3 2023 Nov 13, 2023	SELL	$12.64 - $19.76 $2.5 Million - $3.91 Million	-198,100 Reduced 91.89%	17,476 $222,000
Q2 2023 Aug 11, 2023	BUY	$15.16 - $23.26 $3.27 Million - $5.01 Million	215,576 New	215,576 $3.9 Million
Q4 2022 Feb 13, 2023	BUY	$6.85 - $25.46 $1.27 Million - $4.73 Million	185,652 Added 1759.9%	196,201 $4.36 Million
Q3 2022 Nov 14, 2022	SELL	$6.96 - $11.48 $723 - $1,193	-104 Reduced 0.98%	10,549 $85,000
Q2 2022 Aug 15, 2022	SELL	$5.68 - $15.99 $522 - $1,471	-92 Reduced 0.86%	10,653 $75,000
Q1 2022 May 16, 2022	SELL	$13.16 - $22.64 $3,092 - $5,320	-235 Reduced 2.14%	10,745 $163,000
Q4 2021 Feb 14, 2022	BUY	$19.56 - $32.94 $214,768 - $361,681	10,980 New	10,980 $241,000

Others Institutions Holding FDMT

# of Institutions

144

Shares Held

57.7M

Call Options Held

137K

Put Options Held

111K

View Full List

About 4D Molecular Therapeutics, Inc.

Ticker FDMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,382,400
Market Cap $252M
Description
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...

More about FDMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account